Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience

• Published in: Future oncology (London, England) Vol. 18; no. 24; pp. 2651 - 2659
• Main Authors: Caputo, Francesco, Santini, Chiara, Casadei-Gardini, Andrea, Cerma, Krisida, Bardasi, Camilla, Garajovà, Ingrid, Lattanzi, Elisabetta, Passardi, Alessandro, Rapposelli, Ilario Giovanni, Spallanzani, Andrea, Salati, Massimiliano, Bonetti, Luca Reggiani, Gelmini, Roberta, Meduri, Bruno, Piccoli, Micaela, Pecchi, Annarita, Benatti, Stefania, Piacentini, Federico, Dominici, Massimo, Luppi, Gabriele, Gelsomino, Fabio
• Format: Journal Article
• Language: English
• Published: Future Medicine Ltd 01.08.2022
• Subjects: chemoradiation; colorectal cancer; statins; toxicity; tumor regression
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2021-1646

To investigate the influence of various concomitant medications on outcomes in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. The authors retrospectively identified 246 patients from 2003 to 2018, collecting demographic and clinicopathological data of interest. Odds ratio (OR) was used to assess the association between concomitant drugs and outcomes. The authors found an association between statins and a Dworak regression grade of 3–4 (OR = 8.78; p = 0.01). Furthermore, statins were significantly associated with more frequent chemoradiation-related toxicity (OR = 2.39; p = 0.0098) and chemotherapy dose reduction or discontinuation (OR = 2.26; p = 0.03). Despite higher frequency of radiotherapy and chemotherapy interruption or dose reduction, the concomitant use of statins during neoadjuvant chemoradiation proved to be associated with better tumor regression.